TrialCancer medicine2018

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

David Fogelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.